Investment analysts at Zacks Research reduced their FY2024 earnings estimates for shares of Axsome Therapeutics in a research ...

Empower Moderate Profile Fund earns a Below Average Process Pillar rating. The process is bolstered by the experience of the management team, which averages 18 years at this fund. However ...